Lakefront Biotherapeutics NV (LKFT) fair value analysis
Nasdaq · Updated 2026-10-19
LKFT price how computed
Valuation status
Reports in EURLKFT reports its results in EUR while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for LKFT until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in EUR.
- Last price
- $28.86
- Sector
- Healthcare
- 12-month range
- $26.08–$34.64
- Market cap
- $1.89B
- From 52-week high
- -16.7%
- Shares outstanding
- 65.5M
- Rank in Healthcare by quality score
- #247 of 301
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-16.
Lakefront Biotherapeutics NV is a biopharmaceutical company focused on developing therapies for patients with severe inflammatory and immunological diseases. The company is based in the Netherlands and is listed on the Nasdaq stock exchange.
LKFT currently ranks #247 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in EUR; the trailing P/E is omitted because an EPS in EUR against a US-dollar share price would mislead.
- Market cap
- $1.89B
- Revenue (TTM)
- EUR 991M
- Net margin
- 60.2%
- EPS (TTM)
- EUR 12.33
- Gross margin
- -185.8%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- -30.0%
- Shares outstanding
- 65.5M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 56 · neutral
- 50-day average
- $28.79
- 200-day average
- $30.00
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Earnings how computed
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+100.3%)
2026-03 ▲ beat (+121.6%)
2025-12 ▲ beat (+17628.6%)
2025-09 ▲ beat (+35.7%)
2025-06 ▼ miss (-615.4%)
2025-03 ▲ beat (+638.9%)
2024-09 ▼ miss (-516.7%)
2024-06 ▲ beat (+450.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 1 buy · 4 hold · 1 sell (6 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $30.3
- Target vs last price
- +5.0%
What our data shows for LKFT
- Shares are trading in the lower third of their 12-month price range of $26.08–$34.64.
- The 14-day relative strength index sits at a neutral 56.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- LKFT's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the LKFT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — LKFT's derived indicators showed mixed directional signals this week. The 50/200-day trend state shifted from downtrend to mixed, while the revenue growth band moved from none to declining, indicating deteriorating momentum in the Healthcare sector company's fundamentals.
- 2026-09-17 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is LKFT stock undervalued?
LKFT reports its results in EUR while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for LKFT until same-currency inputs are available.
What is LKFT's TickrTrends verdict?
LKFT is currently marked 'Reports in EUR' - no verdict is published on inputs in two different currencies.
How does LKFT compare to other Healthcare stocks?
LKFT ranks #247 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is LKFT overbought or oversold?
LKFT's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does LKFT usually beat earnings estimates?
Over its last 8 reported quarters LKFT beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about LKFT?
Of 6 analysts covering LKFT, 1 rate it a buy, 4 a hold and 1 a sell - hold-leaning, with a consensus price target of $30.3 (+5.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.